对于扩展阶段小细胞肺癌的维持疗法的未满足需求
Luis Paz-Ares1, Brinda Gupta2, Javier Baena1
1Hospital Universitario 12 de Octubre, H120H120-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & Ciberonc, Madrid, Spain.
Clinical lung cancer
|March 28, 2025
概括
广泛的小细胞肺癌 (SCLC) 需要新的治疗方法. 虽然免疫检查点抑制剂 (ICI) 改善了结果,但复发率仍然很高,因此需要针对这种侵袭性恶性瘤制定新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 癌症研究 癌症研究
背景情况:
- 小细胞肺癌 (SCLC) 是一种具有不良预后的侵袭性恶性瘤,特别是在广泛阶段 (ES) 疾病中.
- 目前的第一线治疗将化疗与免疫检查点抑制剂 (ICI) 结合起来,然后进行ICI维护,提供了提前治疗,但仍然导致复发率高.
- 很大一部分ES-SCLC患者需要二线治疗,这凸显了改善治疗策略的未满足需求.
研究的目的:
- 审查在扩展阶段小细胞肺癌中维持治疗的合理性和现有数据.
- 讨论ES-SCLC管理的当前和新兴治疗剂和预测生物标志物.
- 探索新的治疗策略,以改善SCLC患者的长期存活率.
主要方法:
- 对ES-SCLC第一线维护设置中化疗,ICI和其他药物的现有数据的文献综述.
- 关于预测生物标志物和SCLC亚型的讨论,与治疗选择相关.
- 目前正在开发的新型治疗方法对SCLC的概述.
主要成果:
- 一线化疗与ICI结合,其次是ICI维护,改善了结果,但并不能消除ES-SCLC的高复发率.
- 大约40%的ES-SCLC患者进展到二线治疗,表明当前护理标准的局限性.
- 该综述综合了当前的知识,并确定了在SCLC治疗中未来研究的领域.
结论:
- 尽管ICI取得了进展,但新的维持疗法方法对于改善扩散阶段小细胞肺癌的长期存活至关重要.
- 调查预测生物标志物和探索新的药物,如lurbinectedin,抗体-药物结合物和T细胞参与者是克服治疗耐药性的关键.
- 对创新的治疗策略的持续研究对于解决SCLC的高致死率至关重要.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


